FY2025 Earnings Forecast for THTX Issued By Leede Financial

Theratechnologies Inc. (NASDAQ:THTX) – Stock analysts at Leede Financial cut their FY2025 earnings per share estimates for shares of Theratechnologies in a research report issued to clients and investors on Monday, April 14th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of ($0.17) per share for the year, down from their prior estimate of $0.06. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share.

THTX has been the topic of a number of other reports. Jones Trading raised Theratechnologies from a “hold” rating to a “strong-buy” rating in a report on Friday, April 11th. Research Capitl raised shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Stock Performance

Shares of THTX stock opened at $2.52 on Wednesday. Theratechnologies has a 1 year low of $1.08 and a 1 year high of $3.13. The business’s fifty day moving average is $1.69 and its 200-day moving average is $1.55. The stock has a market cap of $115.87 million, a PE ratio of -25.20 and a beta of 1.11.

Institutional Trading of Theratechnologies

Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. bought a new stake in Theratechnologies in the fourth quarter worth $27,000. Bank of America Corp DE lifted its stake in shares of Theratechnologies by 1,416.7% in the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after buying an additional 15,400 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Theratechnologies during the fourth quarter valued at about $33,000. BNP Paribas Financial Markets bought a new stake in Theratechnologies during the fourth quarter valued at about $36,000. Finally, Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the fourth quarter valued at about $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.